Standardized Fecal Microbiota Transplantation for Ulcerative Colitis

Launched by THE SECOND HOSPITAL OF NANJING MEDICAL UNIVERSITY · Feb 9, 2013

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called fecal microbiota transplantation (FMT) to see if it can help people with moderate to severe ulcerative colitis (UC), which is a type of inflammatory bowel disease. The trial aims to determine how effective and safe this treatment is for patients who have not found relief from other therapies. Researchers will be working with 500 patients to gather information about how FMT might improve their condition.

To participate, you need to have been diagnosed with ulcerative colitis for at least three months and not have had enough success with previous treatments. However, if you have other serious health issues or have had certain treatments in the past, you may not be eligible. If you join the trial, you can expect close monitoring and support throughout the process as researchers gather important data on this potential new treatment. This study is currently looking for participants of all genders between the ages of 21 and 92.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who had been diagnosed with UC through a combination of typical clinical symptoms, endoscopy, and histological criteria for at least 3 months, and patients who failed to achieve satisfactory efficacy for UC from the previous therapies.
• Exclusion Criteria:
• • Patients were excluded if accompanied by other severe diseases, including other intestinal diseases (e.g., Clostridioides difficile infection), malignant neoplasm, cardiopulmonary failure, and serious liver and kidney disease, refused to complete the follow-up, and underwent FMT or WMT before.